Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology

Robert G. Bristow, Brian Alexander, Michael Baumann, Scott V. Bratman, J. Martin Brown, Kevin Camphausen, Peter Choyke, Deborah Citrin, Joseph N. Contessa, Adam Dicker, David G. Kirsch, Mechthild Krause, Quynh Thu Le, Michael Milosevic, Zachary S. Morris, Jann N Sarkaria, Paul M. Sondel, Phuoc T. Tran, George D. Wilson, Henning WillersRebecca K.S. Wong, Paul M. Harari

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.

Original languageEnglish (US)
Pages (from-to)e240-e251
JournalThe Lancet Oncology
Volume19
Issue number5
DOIs
StatePublished - May 1 2018

Fingerprint

Radiation Oncology
Radiotherapy
Guidelines
Immunotherapy
Neoplasms
Precision Medicine
Tumor Microenvironment
Radiation Tolerance
Brachytherapy
Genetic Predisposition to Disease
Prescriptions
Radiation
Mutation
Therapeutics
Research
Genes

ASJC Scopus subject areas

  • Oncology

Cite this

Combining precision radiotherapy with molecular targeting and immunomodulatory agents : a guideline by the American Society for Radiation Oncology. / Bristow, Robert G.; Alexander, Brian; Baumann, Michael; Bratman, Scott V.; Brown, J. Martin; Camphausen, Kevin; Choyke, Peter; Citrin, Deborah; Contessa, Joseph N.; Dicker, Adam; Kirsch, David G.; Krause, Mechthild; Le, Quynh Thu; Milosevic, Michael; Morris, Zachary S.; Sarkaria, Jann N; Sondel, Paul M.; Tran, Phuoc T.; Wilson, George D.; Willers, Henning; Wong, Rebecca K.S.; Harari, Paul M.

In: The Lancet Oncology, Vol. 19, No. 5, 01.05.2018, p. e240-e251.

Research output: Contribution to journalReview article

Bristow, RG, Alexander, B, Baumann, M, Bratman, SV, Brown, JM, Camphausen, K, Choyke, P, Citrin, D, Contessa, JN, Dicker, A, Kirsch, DG, Krause, M, Le, QT, Milosevic, M, Morris, ZS, Sarkaria, JN, Sondel, PM, Tran, PT, Wilson, GD, Willers, H, Wong, RKS & Harari, PM 2018, 'Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology', The Lancet Oncology, vol. 19, no. 5, pp. e240-e251. https://doi.org/10.1016/S1470-2045(18)30096-2
Bristow, Robert G. ; Alexander, Brian ; Baumann, Michael ; Bratman, Scott V. ; Brown, J. Martin ; Camphausen, Kevin ; Choyke, Peter ; Citrin, Deborah ; Contessa, Joseph N. ; Dicker, Adam ; Kirsch, David G. ; Krause, Mechthild ; Le, Quynh Thu ; Milosevic, Michael ; Morris, Zachary S. ; Sarkaria, Jann N ; Sondel, Paul M. ; Tran, Phuoc T. ; Wilson, George D. ; Willers, Henning ; Wong, Rebecca K.S. ; Harari, Paul M. / Combining precision radiotherapy with molecular targeting and immunomodulatory agents : a guideline by the American Society for Radiation Oncology. In: The Lancet Oncology. 2018 ; Vol. 19, No. 5. pp. e240-e251.
@article{72fdb8cb7946401abb4b3ad5eaef18bc,
title = "Combining precision radiotherapy with molecular targeting and immunomodulatory agents: a guideline by the American Society for Radiation Oncology",
abstract = "The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.",
author = "Bristow, {Robert G.} and Brian Alexander and Michael Baumann and Bratman, {Scott V.} and Brown, {J. Martin} and Kevin Camphausen and Peter Choyke and Deborah Citrin and Contessa, {Joseph N.} and Adam Dicker and Kirsch, {David G.} and Mechthild Krause and Le, {Quynh Thu} and Michael Milosevic and Morris, {Zachary S.} and Sarkaria, {Jann N} and Sondel, {Paul M.} and Tran, {Phuoc T.} and Wilson, {George D.} and Henning Willers and Wong, {Rebecca K.S.} and Harari, {Paul M.}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/S1470-2045(18)30096-2",
language = "English (US)",
volume = "19",
pages = "e240--e251",
journal = "The Lancet Oncology",
issn = "1470-2045",
publisher = "Lancet Publishing Group",
number = "5",

}

TY - JOUR

T1 - Combining precision radiotherapy with molecular targeting and immunomodulatory agents

T2 - a guideline by the American Society for Radiation Oncology

AU - Bristow, Robert G.

AU - Alexander, Brian

AU - Baumann, Michael

AU - Bratman, Scott V.

AU - Brown, J. Martin

AU - Camphausen, Kevin

AU - Choyke, Peter

AU - Citrin, Deborah

AU - Contessa, Joseph N.

AU - Dicker, Adam

AU - Kirsch, David G.

AU - Krause, Mechthild

AU - Le, Quynh Thu

AU - Milosevic, Michael

AU - Morris, Zachary S.

AU - Sarkaria, Jann N

AU - Sondel, Paul M.

AU - Tran, Phuoc T.

AU - Wilson, George D.

AU - Willers, Henning

AU - Wong, Rebecca K.S.

AU - Harari, Paul M.

PY - 2018/5/1

Y1 - 2018/5/1

N2 - The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.

AB - The practice of radiation oncology is primarily based on precise technical delivery of highly conformal, image-guided external beam radiotherapy or brachytherapy. However, systematic research efforts are being made to facilitate individualised radiation dose prescriptions on the basis of gene-expressssion profiles that reflect the radiosensitivity of tumour and normal tissue. This advance in precision radiotherapy should complement those benefits made in precision cancer medicine that use molecularly targeted agents and immunotherapies. The personalisation of cancer therapy, predicated largely on genomic interrogation, is facilitating the selection of therapies that are directed against driver mutations, aberrant cell signalling, tumour microenvironments, and genetic susceptibilities. With the increasing technical power of radiotherapy to safely increase local tumour control for many solid tumours, it is an opportune time to rigorously explore the potential benefits of combining radiotherapy with molecular targeted agents and immunotherapies to increase cancer survival outcomes. This theme provides the basis and foundation for this American Society for Radiation Oncology guideline on combining radiotherapy with molecular targeting and immunotherapy agents.

UR - http://www.scopus.com/inward/record.url?scp=85046014118&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046014118&partnerID=8YFLogxK

U2 - 10.1016/S1470-2045(18)30096-2

DO - 10.1016/S1470-2045(18)30096-2

M3 - Review article

C2 - 29726389

AN - SCOPUS:85046014118

VL - 19

SP - e240-e251

JO - The Lancet Oncology

JF - The Lancet Oncology

SN - 1470-2045

IS - 5

ER -